{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:04:02Z","timestamp":1795176242877,"version":"4.10.3"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>MEASURE 5 was a 52-week, Phase III, China-centric study. Eligible patients were randomly assigned (2:1) to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks (q4w). All placebo patients switched to secukinumab 150 mg q4w starting at Week 16. Primary endpoint was Assessments of SpondyloArthritis international Society (ASAS) 20 at Week 16. Randomization was stratified by region (China <jats:italic toggle=\"yes\">vs<\/jats:italic>. non-China).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 458 patients (secukinumab 150 mg, <jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a305; placebo, <jats:italic toggle=\"yes\">N<\/jats:italic>\u200a=\u200a153) randomized, 327 (71.4%) were from China and 131 (28.6%) were not from China. Of these, 97.7% and 97.4% patients completed Week 16 and 91.1% and 95.3% (placebo-secukinumab) patients completed Week 52 of treatment. The primary endpoint was met; secukinumab significantly improved ASAS20 response at Week 16 <jats:italic toggle=\"yes\">vs.<\/jats:italic> placebo (58.4% <jats:italic toggle=\"yes\">vs.<\/jats:italic> 36.6%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.0001); corresponding rate in the Chinese population was 56.0% <jats:italic toggle=\"yes\">vs.<\/jats:italic> 38.5% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.01). All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52. No new or unexpected safety signals were reported up to Week 52.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS. Secukinumab was well tolerated and the safety profile was consistent with previous reports. Efficacy and safety results were comparable between the overall and Chinese populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT02896127; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02896127?term=NCT02896127&amp;draw=2&amp;rank=1.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001099","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T04:01:49Z","timestamp":1599969709000},"page":"2521-2531","source":"Crossref","is-referenced-by-count":47,"title":["Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5"],"prefix":"10.1097","volume":"133","author":[{"given":"Feng","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Guo","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Li","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Immunology, Guangdong General Hospital, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Disease, Upper Borough Walls, Bath BA1 1RL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Min","family":"Qiu","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Haemmerle","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"R1-20230813","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R2-20230813","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11136-010-9771-9","article-title":"Quality of life and related variables in patients with ankylosing spondylitis","volume":"20","author":"Bodur","year":"2011","journal-title":"Qual Life Res"},{"key":"R3-20230813","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis","volume":"15","author":"Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"R4-20230813","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R5-20230813","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/ar2368","article-title":"Rheumatic diseases in China","volume":"10","author":"Zeng","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"R6-20230813","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e32834640a9","article-title":"Similarities and differences between spondyloarthritis in Asia and other parts of the world","volume":"23","author":"Zhang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R7-20230813","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20230813","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R9-20230813","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R10-20230813","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R11-20230813","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4103\/0366-6999.177972","article-title":"Association between dentin matrix protein 1 (rs10019009) polymorphism and ankylosing spondylitis in a Chinese Han population from Shandong province","volume":"129","author":"Liu","year":"2016","journal-title":"Chin Med J"},{"key":"R12-20230813","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","article-title":"Adverse effects of TNF inhibitors in SpA: are they different from RA?","volume":"28","author":"Sampaio-Barros","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R13-20230813","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20230813","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"R15-20230813","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R16-20230813","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150\u200amg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"R17-20230813","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","article-title":"5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial","volume":"2","author":"Marzo-Ortega","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R18-20230813","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1756-185X.13094","article-title":"Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies","volume":"20","author":"Wei","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R19-20230813","first-page":"23","article-title":"Secukinumab demonstrates sustained efficacy in Taiwanese patients with active ankylosing spondylitis: 4-year results from a Phase 3 study, MEASURE 1","volume":"21","author":"Tseng","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R21-20230813","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R22-20230813","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"R23-20230813","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R24-20230813","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R25-20230813","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"key":"R26-20230813","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R27-20230813","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R28-20230813","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20230813","first-page":"1043","article-title":"A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis (in Chinese)","volume":"50","author":"Huang","year":"2011","journal-title":"Chin J Int Med"},{"key":"R30-20230813","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T09:06:06Z","timestamp":1691917566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":29,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001099","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}